Indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults: 🦠 Genotypes 1-6: Universal coverage. 🏥 Liver Status: Safe for patients with compensated cirrhosis or without cirrhosis. 🔄 Treatment-Experienced: Effective for patients who failed prior interferon-based therapy.

Dosage and administration

Packaging: Two separate bottles (28 tablets each). This represents a 4-week supply. ⚠️ ADMINISTRATION PROTOCOL: 💊 Daily Dose: Take ONE tablet of Sofosbuvir and ONE tablet of Daclatasvir together once daily. ⏰ Consistency: Take at the same time every day to prevent viral mutation. 🍽️ Food: Can be taken with or without food. Swallow whole, do not crush. 📅 Duration: Standard course is 12 weeks (3 kits). Extended to 24 weeks for decompensated cirrhosis (under medical supervision).

Pregnancy and breastfeeding (Strictly contraindicated). Co-administration with Amiodarone (Risk of severe bradycardia/heart arrest). Use with strong P-gp inducers (e.g., Rifampin, St. John’s Wort) as they reduce drug efficacy.

Generally well-tolerated with mild side effects: 🤕 Common: Headache, fatigue/tiredness. 🤢 Gastrointestinal: Mild nausea. Rarely: Insomnia or dizziness.

Sofokast + Dacikast — Sofosbuvir 400 mg + 60 mg , 28 + 28 pcs, Aprazer

100% original product

Active ingredient

Sofosbuvir Daclatasvir

Manufacturer

Aprazer

Dosage 400 mg + 60 mg

Dosage form Tablets

Tablets per pack 28 + 28

Sofokast + Dacikast (Sofosbuvir + Daclatasvir) Kit

Name: Sofokast + Dacikast
Brand: Aprazer
SKU: PROD-124
Price: 2329 UAH
Availability: InStock

2329₴ ~~3120₴~~ -25%

Sofokast + Dacikast Kit is a comprehensive dual-drug regimen for the curative treatment of Chronic Hepatitis C.

Manufacturer: Aprazer (India). Note: Sofokast is manufactured under a license from Gilead Sciences, ensuring bioequivalence to the original Sovaldi. This is a "Pan-Genotypic" regimen, meaning it is effective against all major strains of the virus.

Mechanism of Action ("Dual Inhibition"):

The kit combines two Direct-Acting Antivirals (DAAs):

🛡️ Sofosbuvir 400 mg: An NS5B polymerase inhibitor (stops replication).
⚔️ Daclatasvir 60 mg: An NS5A inhibitor (stops viral assembly).

✅ Result: Achieves Sustained Virologic Response (cure) in over 95-98% of patients after a standard 12-week course.

Indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults:

🦠 Genotypes 1-6: Universal coverage.
🏥 Liver Status: Safe for patients with compensated cirrhosis or without cirrhosis.
🔄 Treatment-Experienced: Effective for patients who failed prior interferon-based therapy.

Packaging: Two separate bottles (28 tablets each). This represents a 4-week supply.

⚠️ ADMINISTRATION PROTOCOL:

💊 Daily Dose: Take ONE tablet of Sofosbuvir and ONE tablet of Daclatasvir together once daily.
⏰ Consistency: Take at the same time every day to prevent viral mutation.
🍽️ Food: Can be taken with or without food. Swallow whole, do not crush.
📅 Duration: Standard course is 12 weeks (3 kits). Extended to 24 weeks for decompensated cirrhosis (under medical supervision).

Pregnancy and breastfeeding (Strictly contraindicated).
Co-administration with Amiodarone (Risk of severe bradycardia/heart arrest).
Use with strong P-gp inducers (e.g., Rifampin, St. John’s Wort) as they reduce drug efficacy.

Generally well-tolerated with mild side effects:

🤕 Common: Headache, fatigue/tiredness.
🤢 Gastrointestinal: Mild nausea.
Rarely: Insomnia or dizziness.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 08.03.2026